Biofarm (stock symbol BIO), one of the most important drug manufacturers in Romania, announces increased production of paracetamol-based medicines for the treatment of fever and pain in children to meet increased market demand. We are in the middle of the children's respiratory season and paracetamol-based medicines are very hard to find or are missing from pharmacies. Therefore, we have mobilised and decided to significantly increase production of Bioflu Baby, a paracetamol-based syrup for treating fever and pain in children. Biofarm has an extensive portfolio of products for children colds and flu, and our two manufacturing facilities have the capacity to adapt quickly to any market need, said Catalin Vicol, Biofarm CEO. Biofarm has always focused on aligning itself with market requirements and patient needs, being a company always oriented towards innovation and facilitating access to modern treatment solutions. In the first ten months of 2022, Biofarm ranked 3rd in the Consumer Healthcare (CHC) segment in terms of number of units sold. The Cold Flu therapeutic area saw the highest growth in the Consumer Healthcare (CHC) category, with products such as Bioflu, Carmol, Bixtonim Xylo and Septosol recording double-digit growth. Biofarm currently has two drug factories in Bucharest and a product testing and development unit, and its portfolio of over 200 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory , ORL, cardiovascular ,circulatory, nervous system). With more than 20 representative brands, Biofarm is the market leader in terms of volumes in the reference categories of nine of its brands: Colebil, Triferment, Carbocit, Sennalax, Bixtonim, Carmol, Biofen, Nervocalmin and Cavit. About Biofarm Biofarm® is one of the first Romanian drug and food supplements producers. For 100 years, Biofarm® has stood alongside Romanian specialists in the race to discover the best solutions for maintaining people health. Biofarm® is currently one of the top 10 existing producers on the pharmaceutical market in Romania, a very dynamic and competitive market. Biofarm® has a competitive product portfolio, covering 65 therapeutic areas, and is continuously investing in media, commercial and marketing campaigns to promote its products.
Romanian technology group Visual Fan, best known for its consumer electronics brand Allview, announced that it has signed a partnership with Trina Storage, the energy storage division of the Chinese company Trina Solar, for the development of a battery energy storage system in Topliţa, with a capacity of 65 MWh. This is the first project […]
Romanian energy group OMV Petrom (BVB: SNP) announced its sales revenues dropped by 7% y/y in Q2, resulting in a 1% y/y contraction to RON 17.0 billion (EUR 3.4 billion) in the whole H1, while its net profit plunged by 17% y/y in Q2 and 21% y/y to RON 2.1 billion in H1, according to […]
The volume of building permits for retail spaces in Romania, measured in square meters, surged by 53% y/y to 303 thousand square meters in H1, according to data published by the statistics office INS. The number of projects rose by 42% y/y to 261. The residential construction segment, driven by the individual (as opposed to collective) […]
Romania has completed the renegotiation process of the National Recovery and Resilience Plan (NRRP) with the European Commission, a process that has been going on for more than a year, Minister of Investments and European Projects Dragoș Pîslaru said on July 31, during a press conference, according to
Wizz Air will add a route connecting Brașov, in central Romania, to Katowice, in Poland, beginning next year, the Brașov International Airport announced. The route will become operational on March 31, 2026, with flights operating every Tuesday, Thursday, and Saturday. In the upcoming winter season, the airline will operate seven routes to five countries from […]
IT Genetics, a company specializing in digitalizing services, aims to have its shares tradable at the Bucharest Stock Exchange by the end of this year, with the amount to be raised estimated at approximately EUR 2 million. The ITG group will be listed, not just IT Genetics, which is nevertheless the main pillar of the […]
